Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Hidden fat lumps may sabotage insulin: new study investigates

NCT ID NCT02748434

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether small, hard-to-see fat lumps under the skin (called subclinical lipohypertrophy) change how insulin is absorbed in people with diabetes. Researchers planned to enroll 20 adults with type 1 or type 2 diabetes who use insulin and had these hidden lumps. They measured blood sugar levels using continuous glucose monitors to see if injecting insulin into these areas affects glucose control. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

9 people

The number who actually took part.

Started

Oct 2016

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participation in phase 1 * Type 1 or Type 2 diabetes for at least 2 years * Using insulin to manage diabetes * At least 19 years of age Exclusion Criteria: * Taking insulin secretagogues (gliclazide, glyburide, glipizide * Taking other injectable diabetes medications (i.e. liraglutide, Victoza) * Taking systemic steroids (e.g. prednisone) * Not fluent in speaking and writing English (unless accompanied by a translator)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes mellitus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gerontology Research Lab

    Vancouver, British Columbia, V5Z 1M9, Canada

  • Vancouver General Hospital Diabetes Centre

    Vancouver, British Columbia, V5Z 1M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.